Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bingying Xie
Institution:
Junshi Biosciences (China)
Observed institution:
Junshi Biosciences (China)
ORCID:
0009-0008-4453-5089
Observed ORCID:
0009-0008-4453-5089
OpenAlex ID:
A5102748164
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
·
Clinical Cancer Research
·
20
Supplementary Figure S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S3 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Show more works
View as search
Works count:
11
Citation count:
20
H-index:
1
I10-index:
1
Year
Topic
Type
